Immunophenotypes of systemic lupus erythematosus – features of clinical and laboratory disorders

Immunophenotypes of systemic lupus erythematosus – features of clinical and laboratory disorders

The aim – to evaluate subpopulations of B lymphocytes and features of interferon (IFN) status in patients with systemic lupus erythematosus (SLE), to clarify the relationship of immunological parameters with clinical manifestations of the diseaseMaterial and methods. 139 patients (123 (88%) women an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anastasia S. Avdeeva, Andrey P. Aleksankin, Elena V. Tchetina, Yu. N. Gorbunova, Tatiana V. Popkova, Galina A. Markova, Tatiana A. Panafidina, Evgeny L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2024-09-01
Series:	Научно-практическая ревматология
Subjects:	systemic lupus erythematosus b lymphocyte subpopulations interferon signature immunophenotype
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3606
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical significance of interferon status in patients with systemic lupus erythematosus. Preliminary data
by: T. A. Panafidina, et al.
Published: (2025-03-01)

Effect of biological agents on B-lymphocyte subpopulations in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2019-03-01)

Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus
by: Ellen D. Kaan, et al.
Published: (2024-12-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01)

Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic
by: E. L. Nasonov, et al.
Published: (2021-05-01)

IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE
by: E. L. Nasonov, et al.
Published: (2019-09-01)

Adjunctive anifrolumab for recalcitrant discoid lupus erythematosus in the setting of systemic lupus erythematosus: A case report
by: Gabriela Soto-Canetti, MPH, et al.
Published: (2025-06-01)

Resolution of the Expert Council «The role of type I interferon inhibitor in the treatment of patients with systemic lupus erythematosus»
by: A. M. Lila, et al.
Published: (2021-08-01)

Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01)

Experience with type I interferon inhibitor in systemic lupus erythematosus
by: Ya. A. Leineman, et al.
Published: (2022-08-01)

Clinical significance of leptin in systemic lupus erythematosus
by: L. V. Kondratyeva, et al.
Published: (2021-12-01)

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01)

Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
by: A. A. Baranov, et al.
Published: (2024-06-01)

CLINICAL VALUE OF BAFF AND APRIL CONCENTRATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
by: T. A. Panafidina, et al.
Published: (2016-07-01)

HEART FAILURE IN SYSTEMIC LUPUS ERYTHEMATOSUS: RISK FACTORS AND DIAGNOSTIC FEATURES
by: T. A. Panafidina, et al.
Published: (2018-07-01)

Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis
by: Benjamin Lai, et al.
Published: (2024-10-01)

THE REGISTRY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS, A EURASIAN COHORT (RENAISSANCE)
by: E. A. Aseeva, et al.
Published: (2016-12-01)

GLUCOCORTICOIDS IN THE THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
by: T. M. Reshetnyak, et al.
Published: (2014-07-01)

New Mechanisms and Therapeutic Targets in Systemic Lupus Erythematosus
by: Jingru Tian, et al.
Published: (2025-06-01)

AN OVERVIEW OF THE VI EULAR SCIENTIFIC EDUCATIONAL COURSE DEDICATED TO SYSTEMIC LUPUS ERYTHEMATOSUS (PISA, ITALY, SEPTEMBER 1–6, 2013)
by: T. A. Panafidina
Published: (2014-06-01)

Flare of bullous lupus erythematosus in patients treated with anifrolumab for discoid lupus erythematosus: 2 cases
by: Cécile Lesort, MD, et al.
Published: (2025-04-01)

Association of hyperactivated transposon expression with exacerbated immune activation in systemic lupus erythematosus
by: Frank Qingyun Wang, et al.
Published: (2024-10-01)

Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
by: E. L. Nasonov, et al.
Published: (2021-09-01)

Main circulating CD8<sup>+</sup> T cell subsets in patients with systemic lupus erythematosus
by: S. S. Benevolenskaya, et al.
Published: (2024-03-01)

IMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCE
by: E. V. Suponitskaya, et al.
Published: (2015-03-01)

The impact of disease activity and interferon-α on the nervous system in systemic lupus erythematosus
by: Kristoffer A. Zervides, et al.
Published: (2025-03-01)

Late-onset systemic lupus erythematosus in the elderly
by: N. G. Klyukvina
Published: (2018-01-01)

Rapid resolution of fever and panniculitis after anifrolumab in a patient with systemic lupus erythematosus refractory to standard immunosuppression
by: Shunichiro Hanai, et al.
Published: (2025-08-01)

The expression of interferon-stimulated genes (interferon “signature”) in patients with rheumatoid arthritis (Preliminary results)
by: A. S. Avdeeva, et al.
Published: (2021-01-01)

Systemic lupus erythematosus: new horizons for diagnosis and therapy
by: S. K. Solovyev, et al.
Published: (2020-02-01)

Skin lesions in systemic lupus erythematosus. Part 2: clinical and histological features
by: A. A. Shumilova, et al.
Published: (2022-08-01)

Difficulties in diagnostics of systemic lupus erythematosus
by: N. V. Zilberberg, et al.
Published: (2021-06-01)

Role of inflammation in the development of cardiac autonomic disfunction in patients with systemic lupus erythematosus
by: D. S. Novikova, et al.
Published: (2008-12-01)

Identification and immunoassay of biomarkers associated with T cell exhaustion in systemic lupus erythematosus
by: Yiqing Zheng, et al.
Published: (2025-03-01)

Recent Advances of Type I Interferon on the Regulation of Immune Cells and the Treatment of Systemic Lupus Erythematosus
by: Wang X, et al.
Published: (2025-03-01)

Irreversible organ damages in a cohort of patients with systemic lupus erythematosus (RENAISSANCE)
by: E. A. Aseeva, et al.
Published: (2016-10-01)

SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL RECOMMENDATIONS. PART 1
by: Ekaterina I. Alexeeva, et al.
Published: (2018-04-01)

PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. L. Nasonov, et al.
Published: (2014-06-01)

Clinical features of systemic lupus erythematosus in men depending on testosterone level
by: T. S. Panevin, et al.
Published: (2025-04-01)

According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments
by: T. V. Popkova, et al.
Published: (2019-11-01)